Alkermes plc, of Dublin, disclosed top-line results from FORWARD-1, one of a series of supportive clinical studies in the comprehensive FORWARD phase III pivotal program for the opioid modulator ALKS 5461, a once-daily, oral medicine for major depressive disorder (MDD).